Activins, inhibins, and follistatins: From endocrinology to signaling. A paradigm for the new millennium

Experimental Biology and Medicine

Volumn 227, Issue 9, 2002, Pages 724-752

  Welt, Corrine ^a   Sidis, Yisrael ^a   Keutmann, Henry ^a   Schneyer, Alan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Activin; Activin receptors; Autocrine actions; Endocrinology; Follistatin; Follistatin related protein; FSRP FLRG; Inhibin; Paracrine actions; Signaling; SMADs; Transforming growth factor

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; FOLLISTATIN; INHIBIN; TRANSFORMING GROWTH FACTOR BETA;

AUTOCRINE EFFECT; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; OVARY FOLLICLE DEVELOPMENT; PARACRINE SIGNALING; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0036790467     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222700905     Document Type: Short Survey

References (389)

1. Mottram JC, Cramer W. On the general effects of exposure to radium on metabolism and tumour growth in the rat and the special effects on the testis and pituitary. Q J Exp Physiol Cogn Med Sci 13:209-229. 1923.
2. McCullagh DR. Dual endocrine activity of testes. Science 76:19, 1932.
3. deJong FH. Inhibin. Physiol Reviews 68:555-607, 1988.
4. Rivier J, Spiess J, McClintock R, Vaughan J, Vale W. Purification and partial characterization of inhibin from porcine follicular fluid. Biochem Biophys Res Commun 133:120-127, 1985.
5. Robertson DM, deVos FL, Foulds LM, McLachlan RI, Burger HG, Morgan FJ, Hearn MTW, DeKretser DM. Isolation of a 31 kDa form of inhibin from bovine follicular fluid. Mol Cell Endocrinol 44:271-277, 1986.
6. Mason AJ, Hayflick JS, Ling N, Esch F, Ueno N, Ying S, Guillemin R, Niall HD, Seeburg PH. Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-beta. Nature 318:659-663, 1985.
7. Mason AJ, Niall HD, Seeburg PH. Structure of two human ovarian inhibins. Biochem Biophys Res Commun 135:957-964, 1986.
8. Forage RG, Ring JM, Brown RW, McInerney BV, Cobon GS, Gregson RP, Robertson DM, Morgan FJ, Hearn MTW, Findlay JK, Wettenhall EH, Burger HG, DeKretser DM. Cloning and sequence analysis of cDNA species coding for the two subunits from bovine follicular fluid. Proc Natl Acad Sci USA 83:3091-3095, 1986.
9. Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M, Guillemin R. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 321:779-782, 1986.
10. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, Karr D, Spiess J. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 321:776-779, 1986.
11. Ueno N, Ling N, Ying S-Y, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: A single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA 84:8282-8286, 1987.
12. Robertson DM, Klein R, de Vos FL, McLachlan RI, Wettenhall REH, Hearn MTW, Burger HG, DeKretser DM. The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 149:744-749, 1987.
13. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. Activinbinding protein from rat ovary is follistatin. Science 247:836-838, 1990.
14. Kogawa K, Nakamura T, Sugino K, Takio K, Titani K, Sugino H. Activin-binding protein is present in pituitary. Endocrinology 128:1434-1440, 1991.
15. Mather JP, Woodruff TK, Krummen LA. Paracrine regulation of reproductive function by inhibin and activin. Proc Soc Exp Biol Med 201:1-15, 1992.
16. DePaolo LV, Bicsak TA, Erickson GF, Shimasaki S, Ling N. Follistatin and activin: A potential intrinsic regulatory system within diverse tissues. Proc Soc Exp Med 198:500-512, 1991.
17. DePaolo LV. Inhibins, activins, and follistatins: The saga continues. Proc Soc Exp Biol Med 214:328-339, 1997.
18. Mather JP, Moore A, Li R. Activins, inhibins, and follistatins: Further thoughts on a growing family of regulators. Proc Soc Exp Biol Med 215:209-222, 1997.
19. Phillips DJ, de Kretser DM. Follistatin: A multifunctional regulatory protein. Front Neuroendocrinol 19:287-322, 1998.
20. de Kretser DM, Hedger MP, Phillips DJ. Activin-A and follistatin: Their role in the acute phase reaction and inflammation. J Endocrinol 161:195-198, 1999.
21. Phillips DJ. New developments in the biology of inhibins, activins and follistatins. Trends Endocrinol Metab 12:94-96, 2001.
22. de Kretser DM, Loveland KL, Meehan T, O'Bryan MK, Phillips DJ, Wreford NG. Inhibins, activins and follistatin: Actions on the testis. Mol Cell Endocrinol 180:87-92, 2001.
23. Welt CK, Martin KA, Taylor AE, Lambert-Messerlian GM, Crowley WF Jr, Smith JA, Schoenfeld DA, Hall JE. Frequency modulation of follicle-stimulating hormone (FSH) during the luteal-follicular transition: Evidence for FSH control of inhibin-B in normal women. J Clin Endocrinol Metab 82:2645-2652, 1997.
24. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin-B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401-1405, 1996.
25. Groome N, Illingworth PI, O'Brien M. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 40:717-723, 1994.
26. Lambert-Messerlian GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WFC, Schneyer AL. Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 79:45-50, 1994.
27. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, Spiess J, Rivier J. Chemical and biological characterization of the inhibin family of protein hormones. Rec Prog Horm Res 44:1-34, 1988.
28. Molskness TA, Woodruff TK, Hess DL, Dahl KD, Stouffer RL. Recombinant human inhibin-A administered early in the menstrual cycle alters concurrent pituitary and follicular, plus subsequent luteal, function in rhesus monkeys. J Clin Endocrinol Metab 81:4002-4006, 1996.
29. Stouffer RL, Dahl KD, Hess DL, Woodruff TK, Mather JP, Molskness TA. Systemic and intraluteal infusion of inhibin A or activin A in rhesus monkeys during the luteal phase of the menstrual cycle. Biol Reprod 50:888-895, 1994.
30. Fraser HM, Tsonis CG. Manipulation of inhibin during the lutealfollicular phase transition of the primate menstrual cycle fails to affect FSH secretion. J Endocrinol 142:181-186, 1994.
31. Lahlou N, Chabbert-Buffet N, Christin-Maitre S, Le Nestour E, Roger M, Bouchard P. Main inhibitor of follicle stimulating hormone in the luteal-follicular transition: Inhibin A, oestradiol, or inhibin-B? Hum Reprod 14:1190-1193, 1999.
32. Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 84:105-111, 1999.
33. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin-B secretion is associated with the monotropic FSH rise in older, ovulatory women: A study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 81:2742-2745, 1996.
34. Reame NE, Wyman TL, Phillips DJ, de Kretser DM, Padmanabhan V. Net increase in stimulatory input resulting from a decrease in inhibin-B and an increase in activin A may contribute in part to the rise in follicular phase follicle-stimulating hormone of aging cycling women. J Clin Endocrinol Metab 83:3302-3307, 1998.
35. Santoro N, Adel T, Skurnick JH. Decreased inhibin tone and increased activin A secretion characterize reproductive aging in women. Fertil Steril 71:658-662, 1999.
36. Burger HG, Cahir N, Robertson DM, Groome NP, Dudley E, Green A, Dennerstein L. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women. Clin Endocrinol (Oxf) 48:809-813, 1998.
37. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, Dewailly D. Serum levels of inhibins are differentially altered in patients with polycystic ovary syndrome: Effects of being overweight and relevance to hyperandrogenism. Fertil Steril 73:972-977, 2000.
38. Elting MW, Kwee J, Schats R, Rekers-Mombarg LT, Schoemaker J. The rise of estradiol and inhibin-B after acute stimulation with follicle-stimulating hormone predict the follicle cohort size in women with polycystic ovary syndrome, regularly menstruating women with polycystic ovaries, and regularly menstruating women with normal ovaries. J Clin Endocrinol Metab 86:1589-1595, 2001.
39. Pigny P, Desailloud R, Cortet-Rudelli C, Duhamel A, Deroubaix-Allard D, Racadot A, Dewailly D. Serum alpha-inhibin levels in polycystic ovary syndrome: Relationship to the serum androstenedione level. J Clin Endocrinol Metab 82:1939-1943, 1997.
40. Anderson RA, Groome NP, Baird DT. Inhibin A and inhibin-B in women with polycystic ovarian syndrome during treatment with FSH to induce mono-ovulation. Clin Endocrinol (Oxf) 48:577-584, 1998.
41. Lockwood GM, Muttukrishna S, Groome NP, Matthews DR, Ledger WL. Mid-follicular phase pulses of inhibin-B are absent in polycystic ovarian syndrome and are initiated by successful laparoscopic ovarian diathermy: A possible mechanism regulating emergence of the dominant follicle. J Clin Endocrinol Metab 83:1730-1735, 1998.
42. Fujiwara T, Sidis Y, Welt C, Lambert-Messerlian G, Fox J, Taylor A, Schneyer A. Dynamics of inhibin subunit and follistatin mRNA during development of normal and polycystic ovary syndrome follicles. J Clin Endocrinol Metab 86:4206-4215, 2001.
43. Schneyer AL, Rzucidlo DA, Sluss PM, Crowley WF Jr. Characterization of unique binding kinetics of follistatin and activin or inhbin in serum. Endocrinology 135:667-674, 1994.
44. Demura R, Suzuki T, Tajima S, Mitsuhashi S, Odagiri E, Demura H, Ling N. Human plasma free activin and inhibin levels during the menstrual cycle. J Clin Endocrinol Metab 76:1080-1082, 1993.
45. Vihko KK, Blauer M, Kujansuu E, Vilska S, Alback T, Tuimala R, Tuohimaa P, Punnonen R. Activin-B: Detection by an immunoenzymometric assay in human serum during ovarian stimulation and late pregnancy. Hum Reprod 13:841-846, 1998.
46. Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab 81:3328-3334, 1996.
47. Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor AE. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: Relationship to circulating hormone concentrations. J Clin Endocrinol Metab 85:3319-3330, 2000.
48. Loria P, Petraglia F, Concari M, Bertolotti M, Martella P, Luisi S, Grisolia C, Foresta C, Volpe A, Genazzani AR, Carulli N. Influence of age and sex on serum concentrations of total dimeric activin A. Eur J Endocrinol 139:487-492, 1998.
49. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF, Schneyer AL. The presence of activin, inhibin and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82:3720-3727, 1997.
50. Welt C, Martin KA, Taylor A, Lambert-Messerlian G, Crowley WF Jr, Smith JC, Schoenfeld D, Hall JE. Frequency modulation of Follicle-Stimulating Hormone (FSH) during the luteal-follicular transition: Evidence for FSH control of inhibin-B in normal women. J Clin Endocrinol Metab 82:2645-2652, 1997.
51. Welt CK, Smith ZA, Pauler DK, Hall JE. Differential regulation of inhibin A and inhibin-B by luteinizing hormone, follicle-stimulating hormone, and stage of follicle development. J Clin Endocrinol Metab 86:2531-2537, 2001.
52. Welt CK, Schneyer AL. Differential regulation of inhibin-B and inhibin a by follicle-stimulating hormone and local growth factors in human granulosa cells from small antral follicles. J Clin Endocrinol Metab 86:330-336, 2001.
53. Welt CK, Adams JM, Sluss PM, Hall JE. Inhibin A and inhibin-B responses to gonadotropin withdrawal depends on stage of follicle development. J Clin Endocrinol Metab 84:2163-2169, 1999.
54. Dykema JC, Mayo KE. Two messenger ribonucleic acids encoding the common βB-chain of inhibin and activin have distinct 5′-initiation sites and are differentially regulated in rat granulosa cells. Endocrinology 135:702-711, 1994.
55. Feng Z-M, Li Y-P, Chen C-LC. Analysis of the 5′-flanking regions of rat inhibin alpha- and beta-B-subunit genes suggests two different regulatory mechanisms. Molec Endocrinol 3:1914-1925, 1989.
56. Ardekani AM, Romanelli JC, Mayo KE. Structure of the rat inhibin and activin betaA-subunit gene and regulation in an ovarian granulosa cell line. Endocrinology 139:3271-3279, 1998.
57. Pei L, Dodson R, Schoderbek WE, Maurer RA, Mayo KE. Regulation of the alpha-inhibin gene by cyclic adenosine 3′5′monophosphate after transfection into rat granulosa cells. Molec Endocrinol 5:521-534, 1991.
58. Eramaa M, Ritvos O. Transforming growth factor-β1 and -β2 induce inhibin and activin βB subunit messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Fert Steril 65:954-960, 1996.
59. Eramaa M, Hilden K, Tuuri T, Ritvos O. Regulation of inhibin/activin subunit messenger ribonucleic acids (mRNAs) by activin A and expression of activin receptor mRNAs in cultured human granulosa-luteal cells. Endocrinology 136:4382-4389, 1995.
60. Vanttinen T, Liu J, Liu J, Hyden-Granskog C, Parviainen M, Penttila I, Voutilainen R. Regulation of immunoreactive inhibin A and B secretion in cultured human granulosa-luteal cells by gonadotropins, activin A and insulin-like growth factor type-1 receptor. J Endocrinol 167:289-294, 2000.
61. Jaatinen R, Bondestam J, Raivio T, Hilden K, Dunkel L, Groome N, Ritvos O. Activation of bone morphogenetic protein signaling pathway induces inhibin βB-subunit messenger ribonucleic acid and secreted inhibin-B levels in cultured human granulosa-luteal cells. J Clin Endocrinol Metab 87:1254-1261, 2002.
62. Magoffin DA, Jakimiuk AJ. Inhibin A, inhibin-B and activin A in the follicular fluid of regularly cycling women. Hum Reprod 12:1714-1719, 1997.
63. Seifer DB, Lambert-Messerlian G, Hogan JW, Gardiner AC, Blazar AS, Berk CA. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 67:110-114, 1997.
64. Hall JE, Welt CK, Cramer DW. Inhibin A and inhibin-B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum Reprod 14:409-415, 1999.
65. Corson SL, Gutmann J, Batzer FR, Wallace H, Klein N, Soules MR. Inhibin-B as a test of ovarian reserve for infertile women. Hum Reprod 14:2818-2821, 1999.
66. Hofmann GE, Danforth DR, Seifer DB. Inhibin-B: The physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 69:474-477, 1998.
67. Ravhon A, Lavery S, Michael S, Donaldson M, Margara R, Trew G, Winston R. Dynamic assays of inhibin-B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF. Hum Reprod 15:2297-2301, 2000.
68. Dzik A, Lambert-Messerlian G, Izzo VM, Soares JB, Pinotti JA, Seifer DB. Inhibin B response to EFORT is associated with the outcome of oocyte retrieval in the subsequent in vitro fertilization cycle. Fertil Steril 74:1114-1117, 2000.
69. Eldar-Geva T, Robertson DM, Cahir N, Groome N, Gabbe MP, MacLachlan V, Healy DL. Relationship between serum inhibin A and B and ovarian follicle development after a daily fixed dose administration of recombinant follicle-stimulating hormone. J Clin Endocrinol Metab 85:607-613, 2000.
70. Harkness LM, Baird DT. Morphological and molecular characteristics of living human fetuses between Carnegie stages 7 and 23: Localization of inhibin mRNA alpha and beta a subunits by in-situ hybridization. Hum Reprod Update 3:59-92, 1997.
71. Petraglia F, Garuti GC, Calza L, Roberts V, Giardino L, Genazzani AR, Vale W. Inhibin subunits in human placenta: Localization and messenger ribonucleic acid levels during pregnancy. Am J Obstet Gynecol 165:750-758, 1991.
72. Petraglia F, Calza L, Geruti GC, Abrate M, Giardino L, Genazzani AR, Vale W, Meunier H. Presence and synthesis of inhibin subunits in the human decidua. J Clin Endocrinol Metab 71:487-492, 1990.
73. Petraglia F, Anceschi MM, Calza L, Garuti GC, Fusaro P, Giardino L, Genazzani AR, Vale W. Inhibin and activin in human fetal membranes: Evidence for a local effect on prostaglandin release. J Clin Endocrinol Metab 77:542-548, 1993.
74. Rombauts L, Verhoeven G, Meuleman C, Koninckx PR, Poncelet E. Franchimont P. Dimeric inhibin A and alpha-subunit immunoreactive material in maternal serum during spontaneous and in vitro fertilization pregnancies. J Clin Endocrinol Metab 81:985-989, 1996.
75. Santoro N, Schneyer AL, Ibrahim J, Schmdt CL. Gonadotropin and inhibin concentrations in early pregnancy in women with and without corpora lutea. Obstet Gynecol 79:579-585, 1992.
76. Illingworth PJ, Groome NP, Duncan WC, Grant V, Tovanabutra S, Baird DT, McNeilly AS. Measurement of circulating inhibin forms during the establishment of pregnancy. J Clin Endocrinol Metab 81:1471-1475, 1996.
77. Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab 82:1557-1560, 1997.
78. Lockwood GM, Ledger WL, Barlow DH, Groome NP, Muttukrishna S. Measurement of inhibin and activin in early human pregnancy: Demonstration of fetoplacental origin and role in prediction of earlypregnancy outcome. Biol Reprod 57:1490-1494, 1997.
79. Muttukrishna S, Child TJ, Groome NP, Ledger WL. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 12:1089-1093, 1997.
80. Petraglia F, DeVita D, Gallinelli A, Aguzzoli L, Genazzani AR, Romero R, Woodruff T. Abnormal concentration of maternal serum activin-A in gestational diseases. J Clin Endocrinol Metab 80:558-561, 1995.
81. Woodruff TK, Sluss P, Wang E, Janssen I, Mersol-Barg MS. Activin A and follistatin are dynamically regulated during human pregnancy. J Endocrinol 152:167-174, 1997.
82. Muttukrishna S, George I, Fowler PA, Groome NP, Knight PG. Measurement of serum concentrations of inhibin A during human pregnancy. Clin Endocrinol 42:391-397, 1995.
83. Harada K, Shintani Y, Sakamoto Y, Wakatsuki M, Shitsukawa K, Saito S. Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J Clin Endocrinol Metab 81:2125-2130, 1996.
84. Sakamoto Y, Shintani Y, Harada K, Abe M, Shitsukawa K, Saito S. Determination of free follistatin levels in sera of normal subjects and patients with various diseases. Eur J Endocrinol 135:345-351, 1996.
85. Wakatsuki M, Shintani Y, Abe M, Liu ZH, Shitsukawa K, Saito S. Immunoradiometric assay for follistatin: Serum immunoreactive follistatin levels in normal adults and pregnant women. J Clin Endocrinol Metab 81:630-634, 1996.
86. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for preeclampsia. Lancet 349:1285-1288, 1997.
87. Jenkin G, Ward J, Loose J, Schneider-Kolsky M, Young R, Canny B, O'Connor A, de Kretser D, Wallace E. Physiological and regulatory roles of activin A in late pregnancy. Mol Cell Endocrinol 180:131-138, 2001.
88. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JN, Connor JM. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 334:1231-1236, 1996.
89. Cuckle HS, Holding S, Jones R, Wallace EM, Groome NP. Maternal serum dimeric inhibin A in second trimester Down's syndrome pregnancies. Prenatal Diag 15:385-392, 1995.
90. Canick JA, Lambert-Messerlian GM, Palomaki GE, Schneyer AL, Tumber MB, Knight GJ. Maternal serum dimeric inhibin is elevated in Down syndrome pregnancy. Am J Hum Genet 55:A37, 1994.
91. Wallace EM, Swanston IA, McNeilly AS, Ashby JP, Blundell G, Calder AA, Groome NP. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Clin Endocrinol (Oxf) 44:17-21, 1996.
92. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn 16:143-153, 1996.
93. Lambert-Messerlian GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down's syndrome pregnancy. J Med Screen 3:58-62, 1996.
94. Wallace EM, Crossley JA, Groome NP, Aitken DA. Amniotic fluid inhibin-A in chromosomally normal and Down's syndrome pregnancies. J Endocrinol 152:109-112, 1997.
95. Burger HG, Fuller PJ, Chu S, Mamers P, Drummond A, Susil B, Neva P, Robertson DM. The inhibins and ovarian cancer. Mol Cell Endocrinol 180:145-148, 2001.
96. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N. Inhibin forms in serum from postmenopausal women with ovarian cancers. Clin Endocrinol (Oxf) 50:381-386, 1999.
97. Petraglia F, Luisi S, Pautier P, Sabourin JC, Rey R, Lhomme C, Bidart JM. Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors. J Clin Endocrinol Metab 83:1029-1032, 1998.
98. Burger HG, Robertson DM, Cahir N, Mamers P, Healy DL, Jobling T, Groome N. Characterization of inhibin immunoreactivity in postmenopausal women with ovarian tumours. Clin Endocrinol (Oxf) 44:413-418, 1996.
99. Lambert-Messerlian GM, Steinhoff M, Zheng W, Canick JA, Gajewski WH, Seifer DB, Schneyer AL. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer. Gynecol Oncol 65:512-516, 1997.
100. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF Jr, Schneyer AL. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82:3720-3727, 1997.
101. Boggess JF, Soules MR, Goff BA, Greer BE, Cain JM, Tamimi HK. Serum inhibin and disease status in women with ovarian granulosa cell tumors. Gynecol Oncol 64:64-69, 1997.
102. Jobling T, Mamers P, Healy DL, MacLachlan V, Burger HG, Quinn M, Rome R, Day AJ. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 55:285-289, 1994.
103. Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M, deBruijn WA. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 321:790-793, 1989.
104. Illingworth PJ, Groome NP, Byrd W, Rainey WE, McNeilly AS, Mather JP, Bremner WJ. Inhibin-B: A likely candidate for the physiologically important form of inhibin in men. J Clin Endocrinol Metab 81:1321-1325, 1996.
105. Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ. Serum inhibin-B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 81:3341-3345, 1996.
106. Andersson AM, Muller J, Skakkebaek NE. Different roles of prepubertal and postpubertal germ cells and Sertoli cells in the regulation of serum inhibin-B levels. J Clin Endocrinol Metab 83:4451-4458, 1998.
107. Roberts V, Meunier H, Sawchenko PE, Vale W. Differential production and regulation of inhibin subunits in rat testicular cell types. Endocrinology 125:2350-2359, 1989.
108. Shaha C, Morris P, Chen CC, Vale W, Bardin CW. Immunostainable inhibin subunits are in multiple types of testicular cells. Endocrinology 125:1941-1950, 1989.
109. Majdic G, McNeilly AS, Sharpe RM, Evans LR, Groome NP, Saunders PT. Testicular expression of inhibin and activin subunits and follistatin in the rat and human fetus and neonate and during postnatal development in the rat. Endocrinology 138:2136-2147, 1997.
110. Anderson RA, Irvine DS, Balfour C, Groome NP, Riley SC. Inhibin B in seminal plasma: Testicular origin and relationship to spermatogenesis. Hum Reprod 13:920-926, 1998.
111. Zhang T, Zhou HM, Liu YX. Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes. Mol Hum Reprod 3:223-231, 1997.
112. Anderson RA, Evans LW, Irvine DS, McIntyre MA, Groome NP, Riley SC. Follistatin and activin A production by the male reproductive tract. Hum Reprod 13:3319-3325, 1998.
113. Jensen TK, Andersson AM, Hjollund NH, Scheike T, Kolstad H, Giwercman A, Henriksen TB, Ernst E, Bonde JP, Olsen J, McNeilly A, Groome NP, Skakkebaek NE. Inhibin B as a serum marker of spermatogenesis: Correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men. J Clin Endocrinol Metab 82:4059-4063, 1997.
114. Seminara SB, Boepple PA, Nachtigall LB, Pralong FP, Khoury RH, Sluss PM, Lecain AE, Crowley WF Jr. Inhibin B in males with gonadotropin-releasing hormone (GnRH) deficiency: Changes in serum concentration after shortterm physiologic GnRH replacement-a clinical research center study. J Clin Endocrinol Metab 81:3692-3696, 1996.
115. Nachtigall LB, Boepple PA, Seminara SB, Khoury RH, Sluss PM, Lecain AE, Crowley WF Jr. Inhibin B secretion in males with gonadotropin-releasing hormone (GnRH) deficiency before and during long-term GnRH replacement: Relationship to spontaneous puberty, testicular volume, and prior treatment-a clinical research center study. J Clin Endocrinol Metab 81:3520-3525, 1996.
116. von Eckardstein S, Simoni M, Bergmann M, Weinbauer GF, Gassner P, Schepers AG, Nieschlag E. Serum inhibin-B in combination with serum follicle-stimulating hormone (FSH) is a more sensitive marker than serum FSH alone for impaired spermatogenesis in men, but cannot predict the presence of sperm in testicular tissue samples. J Clin Endocrinol Metab 84:2496-2501, 1999.
117. Ramaswamy S, Pohl CR, McNeilly AS, Winters SJ, Plant TM. The time course of follicle-stimulating hormone suppression by recombinant human inhibin A in the adult male rhesus monkey (Macaca mulatta). Endocrinology 139:3409-3415, 1998.
118. Byrd W, Bennett MJ, Carr BR, Dong Y, Wians F, Rainey W. Regulation of biologically active dimeric inhibin A and B from infancy to adulthood in the male. J Clin Endocrinol Metab 83:2849-2854, 1998.
119. Andersson AM, Juul A, Petersen JH, Muller J, Groome NP, Skakkebaek NE. Serum inhibin-B in healthy pubertal and adolescent boys: Relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone, and estradiol levels. J Clin Endocrinol Metab 82:3976-3981, 1997.
120. Mann DR, Akinbami MA, Wallen K, Gould KG, Groome NP, Swanston I, McNeilly AS, Fraser HM. Inhibin-B in the male rhesus monkey: Impact of neonatal gonadotropin-releasing hormone antagonist treatment and sexual development. J Clin Endocrinol Metab 82:1928-1933, 1997.
121. Crofton PM, Illingworth PJ, Groome NP, Stirling HF, Swanston I, Gow S, Wu FC, McNeilly A, Kelnar CJ. Changes in dimeric inhibin A and B during normal early puberty in boys and girls. Clin Endocrinol (Oxf) 46:109-114, 1997.
122. Young J, Couzinet B, Chanson P, Brailly S, Loumaye E, Schaison G. Effects of human recombinant luteinizing hormone and folliclestimulating hormone in patients with acquired hypogonadotropic hypogonadism: Study of Sertoli and Leydig cell secretions and interactions. J Clin Endocrinol Metab 85:3239-3244, 2000.
123. Foresta C, Bettella A, Merico M, Garolla A, Plebani M, Ferlin A, Rossato M. FSH in the treatment of oligozoospermia. Mol Cell Endocrinol 161:89-97, 2000.
124. Kinniburgh D, Anderson RA. Differential patterns of inhibin secretion in response to gonadotrophin stimulation in normal men. Int J Androl 24:95-101, 2001.
125. Pineau C, Sharpe RM, Saunders PTK, Gerard N, Jegou B. Regulation of Sertoli cell inhibin production and of inhibin α-subunit mRNA levels by specific germ cell types. Mol Cell Endocrinol 72:13-22, 1990.
126. Bicsak TA, Vale W, Vaughan J, Tucker EM, Cappel S, Hsueh AJW. Hormonal regulation of inhibin production by cultured Sertoli cells. Mol Cell Endocrinol 49:211-217, 1987.
127. Morris PL, Vale W, Cappel S, Bardin CW. Inhibin production by primary Sertoli cell-enriched cultures: Regulation by folliclestimulating hormone, androgens, and epidermal growth factor. Endocrinology 122:717-725, 1988.
128. Toebosch AMW, Robertson DM, Trapman J, Klassen P, dePaus RA, deJong FH, Grootegoed JA. Effects of FSH and IGF-1 on immature rat Sertoli cells: Inhibin alpha- and beta-subunit mRNA levels and inhibin secretion. Mol Cell Endocrinol 55:101-105, 1988.
129. Krummen LA, Toppari J, Kim WH, Morelos BS, Ahmad N, Swerdloff RS, Ling N, Shimasaki S, Esch F, Bhasin S. Regulation of testicular inhibin subunit messenger ribonucleic acid levels in vivo: Effects of hypophysectomy and selective follicle-stimulating hormone replacement. Endocrinology 125:1630-1637, 1989.
130. Cortes D, Muller J, Skakkebaeck NE. Proliferation of Sertoli cells during development of the human testis assessed by stereological methods. Int J Andro 10:589-596, 1987.
131. Mueller J, Skakkebaeck NE. Quantification of germ cells and seminiferous tubules by stereological examination of testicles from 50 boys who suffered from sudden death. Int J Androl 6:143-156, 1983.
132. Raivio T, Toppari J, Perheentupa A, McNeilly AS, Dunkel L. Treatment of prepubertal gonadotrophin-deficient boys with recombinant human follicle-stimulating hormone. Lancet 350:263-264, 1997.
133. Sharpe RM, Turner KJ, McKinnell C, Groome NP, Atanassova N, Millar MR, Buchanan DL, Cooke PS. Inhibin B levels in plasma of the male rat from birth to adulthood: Effect of experimental manipulation of Sertoli cell number. J Androl 20:94-101, 1999.
134. Ramaswamy S, Marshall GR, McNeilly AS, Plant TM. Evidence that in a physiological setting Sertoli cell number is the major determinant of circulating concentrations of inhibin-B in the adult male rhesus monkey (Macaca mulatta). J Androl 20:430-434, 1999.
135. Sharpe RM. Regulation of spermatogenesis. In Knobil E, Neill JD, Eds. The physiology of Reproduction. New York: pp 1363-1434, 1994
136. Foresta C, Bettella A, Rossato M, La Sala G, De Paoli M, Plebani M. Inhibin B plasma concentrations in oligozoospermic subjects before and after therapy with follicle stimulating hormone. Hum Reprod 14:906-912, 1999.
137. Anderson RA, Wallace EM, Groome NP, Bellis AJ, Wu FC. Physiological relationships between inhibin-B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone. Hum Reprod 12:746-751, 1997.
138. Allenby G, Foster PMD, Sharpe RM. Evidence that secretion of immunoactive inhibin by seminiferous tubules from the adult rat testis is regulated by specific germ cell types: Correlation between in vivo and in vitro studies. Endocrinology 128:467-475, 1991.
139. Carreau S. Human Sertoli cells produce inhibin in vitro: An additional marker to assess the seminiferous epithelium development. Hum Reprod 10:1947-1949, 1995.
140. Foresta C, Bettella A, Petraglia F, Pistorello M, Luisi S, Rossato M. Inhibin B levels in azoospermic subjects with cytologically characterized testicular pathology. Clin Endocrinol (Oxf) 50:695-701, 1999.
141. Zhengwei Y, Wreford NG, Royce P, de Kretser DM, McLachlan RI. Stereological evaluation of human spermatogenesis after suppression by testosterone treatment: Heterogeneous pattern of spermatogenic impairment. J Clin Endocrinol Metab 83:1284-1291, 1998.
142. Pierik FH, Vreeburg JT, Stijnen T, De Jong FH, Weber RF. Serum inhibin-B as a marker of spermatogenesis. J Clin Endocrinol Metab 83:3110-3114, 1998.
143. Klingmuller D, Haidl G. Inhibin B in men with normal and disturbed spermatogenesis. Hum Reprod 12:2376-2378, 1997.
144. Wallace EM, Groome NP, Riley SC, Parker AC, Wu FC. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: A prospective longitudinal study. J Clin Endocrinol Metab 82:3111-3115, 1997.
145. Ballesca JL, Balasch J, Calafell JM, Alvarez R, Fabregues F, de Osaba MJ, Ascaso C, Vanrell JA. Serum inhibin-B determination is predictive of successful testicular sperm extraction in men with nonobstructive azoospermia. Hum Reprod 15:1734-1738, 2000.
146. Sugawara M, Depaolo L, Nakatani A, DiMarzo SJ, Ling N. Radioimmunoassay of follistatin: Application for in vitro fertilization
147. Gilfillan CP, Robertson DM. Development and validation of a radioimmunoassay for follistatin in human serum. Clin Endocrinol 41:453-461, 1994.
148. Khoury RH, Wang QF, Crowley WF, Hall JE, Schneyer AL, Toth T, Midgley AR, Sluss PM. Serum follistatin levels in women: Evidence against an endocrine function of ovarian follistatin. J Clin Endocrinol Metab 80:1361-1368, 1995.
149. Schneyer AL, Hall HA, Lambert-Messerlian GM, Wang QF, Sluss PM, Crowley WF. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically. Endocrinology 137:240-247, 1996.
150. McConnell D, Wang QF, Sluss P, Bolf N, Khoury R, Schneyer AL, Midgley AR Jr, Reame NE, Crowley WF Jr, Padmanabhan V. A two site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab 83:851-858, 1998.
151. Evans LW, Muttukrishna S, Groome NP. Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for human follistatin. J Endocrinol 156:275-282, 1998.
152. Schneider-Kolsky M, D'Antona D, Evans LW, Taylor N, O'Connor A, Groome NP, de Kretser D, Wallace EM. Maternal serum total activin A and follistatin in pregnancy and parturition. Br J Obstet Gynaecol 107:995-1000, 2000.
153. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: A cross-sectional and longitudinal study. Hum Reprod 14:827-832, 1999.
154. Wang QF, Smith P, Sluss PM. Development of a two-site solid phase immunochemiluminescent assay for measurement of total human follistatin-315. Proceedings of the 81st Annual Meeting of Endocrine Society, San Diego, CA, 1999. Abst # P3-505, 546, 1999.
155. Goodman SA, Albano R, Wardle FC, Matthews G, Tannahill D, Dale L. BMP1-related metalloproteinases promote the development of ventral mesoderm in early Xenopus embryos. Dev Biol 195:144-157, 1998.
156. Connors SA, Trout J, Ekker M, Mullins MC. The role of tolloid/mini fin in dorsoventral pattern formation of the zebrafish embryo. Development 126:3119-3130, 1999.
157. Piccolo S, Agius E, Lu B, Goodman S, Dale L, De Robertis EM. Cleavage of chordin by Xolloid metalloprotease suggests a role for proteolytic processing in the regulation of Spemann Organizer activity. Cell 91:407-416, 1997.
158. Matzuk MM, Kumar TR, Shou W, Coerver KA, Lau AL, Behringer RR, Finegold MJ. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Horm Res 51:123-154, 1996.
159. Peng C, Mukai ST. Activins and their receptors in female reproduction. Biochem Cell Biol 78:261-279, 2000.
160. Corrigan AZ, Bilezikjian LM, Carroll RS, Bald LN, Schmelzer CH, Fendly BM, Mason AJ, Chin WW, Schwall RH, Vale W. Evidence for an autocrine role of activin B within anterior pituitary cultures. Endocrinology 128:1682-1684, 1991.
161. Matzuk MM, Kumar TR, Bradley A. Different phenotypes for mice deficient in either activins or activin receptor type II. Nature 374:356-360, 1995.
162. Carroll RS, Corrigan AZ, Gharib SD, Vale W, Chin WW. Inhibin, activin, and follistatin: Regulation of follicle-stimulating hormone messenger ribonucleic acid levels. Mol Endocrinol 3:1969-1976, 1989.
163. Weiss J, Harris PE, Halvorson LM, Crowley WF, Jameson JL. Dynamic regulation of follicle-stimulating hormone-beta messinger ribonucleic acid levels by activin and gonadotropin-releasing hormone in perifused rat pituitary cells. Endocrinology 131:1403-1408, 1992.
164. Bilezikjian LM, Vaughan JM, Vale WW. Characterization and the regulation of inhibin/activin subunit proteins of cultured rat anterior pituitary cells. Endocrinology 133:2545-2553, 1993.
165. Pernasetti F, Vasilyev VV, Rosenberg SB, Bailey JS, Huang HJ, Miller WL, Mellon PL. Cell-specific transcriptional regulation of follicle-stimulating hormone-beta by activin and gonadotropinreleasing hormone in the LbetaT2 pituitary gonadotrope cell model. Endocrinology 142:2284-2295, 2001.
166. Huang HJ, Sebastian J, Strahl BD, Wu JC, Miller WL. The promoter for the ovine follicle-stimulating hormone-beta gene (FSHbeta) confers FSHbeta-like expression on luciferase in transgenic mice: Regulatory studies in vivo and in vitro. Endocrinology 142:2260-2266, 2001.
167. Norwitz ER, Xu S, Jeong K, Bedecarrats GY, Winebrenner LD, Chin WW, Kaiser UB. Activin A augments GnRH-mediated transcriptional activation of the mouse GnRH receptor gene. Endocrinology 143:985-997, 2002.
168. Bilezikjian LM, Blount AL, Corrigan AZ, Leal A, Chen Y, Vale WW. Actions of activins, inhibins and follistatins: Implications in anterior pituitary function. Clin Exp Pharmacol Physiol 28:244-248, 2001.
169. Roberts V, Meunier H, Vaughan J, Rivier J, Rivier C, Vale W, Sawchenko P. Production and regulation of inhibin subunits in pituitary gonadotropes. Endocrinology 124:552-554, 1989.
170. Dalkin AC, Gilrain JT, Marshall JC. Ovarian regulation of pituitary inhibin subunit and activin receptor type II gene expression: Evidence for a nonsteroidal inhibitory substance. Endocrinology 135:944-949, 1994.
171. Mathews LS, Vale WW. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 65:973-982, 1991.
172. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404:411-414, 2000.
173. Bernard DJ, Chapman SC, Woodruff TK. Mechanisms of inhibin signal transduction. Recent Prog Horm Res 56:417-450, 2001.
174. Halvorson LM, Weiss J, Bauer-Dantoin AC, Jameson JL. Dynamic regulation of pituitary follistatin messenger ribonucleic acids during the rat estrous cycle. Endocrinology 134:1247-1253, 1994.
175. Dalkin AC, Haisenleder DJ, Gilrain JT, Aylor K, Yasin M, Marshall JC. Gonadotropin-releasing hormone regulation of gonadotropin subunit gene expression in female rats: Actions on follicle-stimulating hormone beta messenger ribonucleic acid (mRNA) involve differential expression of pituitary activin (beta-B) and follistatin mRNAs. Endocrinology 140:903-908, 1999.
176. Kirk SE, Dalkin AC, Yasin M, Haisenleder DJ, Marshall JC. Gonadotropin-releasing hormone pulse frequency regulates expression of pituitary follistatin messenger ribonucleic acid: A mechanism for differential gonadotrope function. Endocrinology 135:876-880, 1994.
177. Besecke LM, Guendner MJ, Schneyer AL, Bauer-Dantoin AC, Jameson JL, Weiss J. Gonadotropin-releasing hormone regulates follicle-stimulating hormone-β gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology 137:3667-3673, 1996.
178. Fox SR, Smith MS. Changes in the pulsatile pattern of luteinizing hormone secretion during the rat estrous cycle. Endocrinology 116:1485-1492, 1985.
179. Levine JE, Bethea CL, Spies HG. In vitro gonadotropin-releasing hormone release from hypothalamic tissues of ovariectomized estrogen-treated cynomolgus macaques. Endocrinology 116:431-438, 1985.
180. Filicori M, Santoro N, Merriam GR, Crowley WF Jr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab 62:1136-1144, 1986.
181. Marshall JC, Dalkin AC, Haisenleder DJ, Paul SJ, Ortolano GA, Kelch RP. Gonadotropin-releasing hormone pulses: Regulators of gonadotropin synthesis and ovulatory cycles. Recent Prog Horm Res 47:155-187, 1991.
182. Levine JE, Ramirez VD. Luteinizing hormone-releasing hormone release during the rat estrous cycle and after ovariectomy, as estimated with push-pull cannulae. Endocrinology 111:1439-1448, 1982.
183. Besecke LM, Guendner MJ, Sluss PA, Polak AG, Woodruff TK, Jameson JL, Bauer-Dantoin AC, Weiss J. Pituitary follistatin regulates activin-mediated production of follicle-stimulating hormone during the rat estrous cycle. Endocrinology 138:2841-2848, 1997.
184. Burger LL, Dalkin AC, Aylor KW, Workman LJ, Haisenleder DJ, Marshall JC. Regulation of gonadotropin subunit transcription after ovariectomy in the rat: Measurement of subunit primary transcripts reveals differential roles of GnRH and inhibin. Endocrinology 142:3435-3442, 2001.
185. Dalkin AC, Haisenleder DJ, Gilrain JT, Aylor K, Yasin M, Marshall JC. Regulation of pituitary follistatin and inhibin/activin subunit messenger ribonucleic acids (mRNAs) in male and female rats: Evidence for inhibin regulation of follistatin mRNA in females. Endocrinology 139:2818-2823, 1998.
186. Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells. Endocrinology 142:1065-1072, 2001.
187. Dalkin AC, Haisenleder DJ, Gilrain JT, Aylor K, Yasin M. Marshall JC. Regulation of pituitary follistatin and inhibin/activin subunit messenger ribonucleic acids (mRNAs) in male and female rats: Evidence for inhibin regulation of follistatin mRNA in females. Endocrinology 139:2818-2823, 1998.
188. Huang HJ, Wu JC, Su P, Zhirnov O, Miller WL. A novel role for bone morphogenetic proteins in the synthesis of follicle-stimulating hormone. Endocrinology 142:2275-2283, 2001.
189. Woodruff TK, Lyon RJ, Hansen SE, Rice GC, Mather JP. Inhibin and activin locally regulate rat ovarian folliculogenesis. Endocrinology 127:3196-3205, 1990.
190. El Hefnawy T, Zeleznik AJ. Synergism between FSH and activin in the regulation of proliferating cell nuclear antigen (PCNA) and cyclin D2 expression in rat granulosa cells. Endocrinology 142:4357-4362, 2001.
191. Findlay JK. An update on the roles of inhibin, activin, and follistatin as local regulators of folliculogenesis. Biol Reprod 48:15-23, 1993.
192. Nakamura T, Sugino S, Titani K, Sugino H. Follistatin, an activin binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J Biol Chem 266:19432-19437, 1991.
193. Delbaere A, Sidis Y, Schneyer AL. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinomaderived cell line (PA-1): Regulation by cell surface follistatin. Endocrinology 140:2463-2470, 1999.
194. Cataldo NA, Rabinovici J, Fujimoto VY, Jaffe RB. Follistatin antagonizes effects of activin-A on steroidogenesis in human luteinizing granulosa cells. J Clin Endocrinol Metab 79:272-277, 1994.
195. Hillier SG. Regulatory functions for inhibin and activin in human ovaries. J Endocrinol 131:171-175, 1991.
196. Roberts VJ, Barth S, El-Roeiy A, Yen SS. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum durng the human menstrual cycle. J Clin Endocrinol Metab 77:1402-1410, 1993.
197. Schwall RH, Mason AJ, Wilcox JN, Bassett SG, Zeleznik AJ. Localization of inhibin/activin subunit mRNAs within the primate ovary. Molec Endocrinol 4:75-79, 1990.
198. Schneyer A, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor A. Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: Relationship to circulating hormone concentrations. J Clin Endocrinol Metab 85:3319-3330, 2000.
199. Roberts VJ, Barth S, El-Roeiy A, Yen SSC. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. J Clin Endocrinol Metab 79:1434-1439, 1994.
200. Schneyer AL. Intrafollicular inhibin/activin/follistatin in maturing human follicles across the normal menstrual cycle: Comparison to PCOS follicles. Proceedings of the 81st Annual Meeting of Endocrine Society, San Diego, CA. Abst # S45-2. 1999.
201. Freiman RN, Albright SR, Zheng S, Sha WC, Hammer RE, Tjian R. Requirement of tissue-selective TBP-associated factor TAFII105 in ovarian development. Science 293:2084-2087, 2001.
202. Matzuk MM, Finegold MJ, Su JJ, Hsueh AJW, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313-319, 1992.
203. Vassalli A, Matzuk MM, Gardner HA, Lee KF, Jaenisch R. Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes Dev 8:414-427, 1994.
204. Brown CW, Houston-Hawkins DE, Woodruff TK, Matzuk MM. Insertion of Inhbb into the Inhba locus rescues the Inhba-null phenotype and reveals new activin functions. Nat Genet 25:453-457, 2000.
205. Guo Q, Kumar TR, Woodruff TW, Hadsell LA, DeMayo FJ, Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol 12:96-106, 1998.
206. Cho BN, McMullen ML, Pei L, Yates CJ, Mayo KE. Reproductive deficiencies in transgenic mice expressing the rat inhibin alpha-subunit gene. Endocrinology 142:4994-5004, 2001.
207. McMullen ML, Cho BN, Yates CJ, Mayo KE. Gonadal pathologies in transgenic mice expressing the rat inhibin alpha-subunit. Endocrinology 142:5005-5014, 2001.
208. Li R, Phillips DM, Mather JP. Activin promotes ovarian follicle development. Endocrinology 136:849-856, 1995.
209. Smitz J, Cortvrindt R, Hu Y, Vanderstichele H. Effects of recombinant activin A on in vitro culture of mouse preantral follicles. Mol Reprod Dev 50:294-304, 1998.
210. Liu X, Andoh K, Yokota H, Kobayashi J, Abe Y, Yamada K, Mizunuma H. Ibuki Y. Effects of growth hormone, activin, and follistatin on the development of preantral follicle from immature female mice. Endocrinology 139:2342-2347, 1998.
211. Yokota H, Yamada K, Liu X, Kobayashi J, Abe Y, Mizunuma H, Ibuki Y. Paradoxical action of activin A on folliculogenesis in immature and adult mice. Endocrinology 138:4572-4576, 1997.
212. Liu X, Andoh K, Abe Y, Kobayashi J, Yamada K, Mizunuma H, Ibuki Y. A comparative study on transforming growth factor-beta and activin A for preantral follicles from adult, immature, and diethylstilbestrol-primed immature mice. Endocrinology 140:2480-2485, 1999.
213. Mizunuma H, Liu X, Andoh K, Abe Y, Kobayashi J, Yamada K, Yokota H, Ibuki Y, Hasegawa Y. Activin from secondary follicles causes small preantral follicles to remain dormant at the resting stage. Endocrinology 140:37-42, 1999.
214. Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N, Matzuk MM. Growth differentiation factor-9 is required during early ovarian folliculogenesis. Nature 383:531-535, 1996.
215. Erickson GF, Shimasaki S. The physiology of folliculogenesis: The role of novel growth factors. Fertil Steril 76:943-949, 2001.
216. Pang Y, Ge W. Activin stimulation of zebrafish oocyte maturation in vitro and its potential role in mediating gonadotropin-induced oocyte maturation. Biol Reprod 61:987-992, 1999.
217. Sadatsuki M, Tsutsumi O, Yamada R, Muramatsu M, Taketani Y. Local regulatory effects of activin A and follistatin on meiotic maturation of rat oocytes. Biochem Biophys Res Commun 196:388-395, 1993.
218. Itoh M, Igarashi M, Yamada K, Hasegawa Y, Seki M, Eto Y, Shibai H. Activin A stimulates meiotic maturation of the rat oocyte in vitro. Biochem Biophys Res Commun 166:1479-1484, 1990.
219. Alak BM, Coskun S, Friedman CI, Kennard EA, Kim MH, Seifer DB. Activin A stimulates meiotic maturation of human oocytes and modulates granulosa cell steroidogenesis in vitro. Fertil Steril 70:1126-1130, 1998.
220. Pang Y, Ge W. Epidermal growth factor and TGF α promote zebrafish oocyte maturation in vitro: Potential role of the ovarian activin regulatory system. Endocrinology 143:47-54, 2002.
221. Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T, Schneyer AL. Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: Evidence for activin's paracrine signaling from granulosa cells to oocytes. Biol Reprod 59:807-812, 1998.
222. Munz B, Smola H, Engelhardt F, Bleuel K, Brauchle M, Lein I, Evans LW, Huylebroeck D, Balling R, Werner S. Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. EMBO J 18:5205-5215, 1999.
223. Munz B, Tretter YP, Hertel M, Engelhardt F, Alzheimer C, Werner S. The roles of activins in repair processes of the skin and the brain. Mol Cell Endocrinol 180:169-177, 2001.
224. Kawakami S. Fujii Y, Winters SJ. Follistatin production by skin fibroblasts and its regulation by dexamethasone, Mol Cell Endocrinol 172:157-167, 2001.
225. Matzuk MM, Lu N, Vogel HJ, Sellheyer K, Roop DR, Bradley A. Multiple defects and perinatal death in mice deficient in follistatin. Nature 374:360-363, 1995.
226. Matzuk MM, Kumar TR, Vassilli A, Bickenbach RR, Roop DR, Jaenisch R, Bradley A. Functional analysis of activins during mammalian development. Nature 374:354-356, 1995.
227. Hubner G, Hu Q, Smola H, Werner S. Strong induction of activin expression after injury suggests an important role of activin in wound repair. Dev Biol 173:490-498, 1996.
228. Shiozaki S, Tajima T, Zhang YQ, Furukawa M, Nakazato Y, Kojima I. Impaired differentiation of endocrine and exocrine cells of the pancreas in transgenic mouse expressing the truncated type II activin receptor. Biochim Biophys Acta 1450:1-11, 1999.
229. Ritvos O, Tuuri T, Eramaa M, Sainio K, Hilden K, Saxen L, Gilbert SF. Activin disrupts epithelial branching morphogenesis in developing glandular organs of the mouse. Mech Dev 50:229-245, 1995.
230. Montesano R, Schaller G, Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 66:697-711, 1991.
231. Montesano R, Matsumoto K, Nakamura T, Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67:901-908, 1991.
232. Maeshima A, Shiozaki S, Tajima T, Nakazato Y, Naruse T. Kojima I. Number of glomeruli is increased in the kidney of transgenic mice expressing the truncated type II activin receptor. Biochem Biophys Res Commun 268:445-449, 2000.
233. Kojima I, Maeshima A, Zhang Y. Role of the activin-follistatin system in the morphogenesis and regeneration of the renal tubules. Mol Cell Endocrinol 180:179-182, 2001.
234. Kogure K, Zhang YQ, Kanzaki M, Omata W, Mine T, Kojima I. Intravenous administration of follistatin: Delivery to the liver and effect on liver regeneration after partial hepatectomy. Hepatology 24:361-366, 1996.
235. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137-161, 1998.
236. Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H. Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun 142:1095-1103, 1987.
237. Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 330:765-767, 1987.
238. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM. Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 180:155-162, 2001.
239. Phillips DJ, Hedger MP, McFarlane JR, Klein R, Clarke IJ, Tilbrook AJ, Nash AD, de Kretser DM. Follistatin concentrations in male sheep increase following sham castration/castration or injection of interleukin-1 beta. J Endocrinol 151:119-124, 1996.
240. Sakai R, Eto Y. Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol 180:183-188, 2001.
241. Sakai R, Eto Y, Hirafuji M, Shinoda H. Activin release from bone coupled to bone resorption in organ culture of neonatal mouse calvaria. Bone 26:235-240, 2000.
242. Funaba M, Ogawa K, Murata T, Fujimura H, Murata E, Abe M, Takahashi M, Torii K. Follistatin and activin in bone: Expression and localization during endochondral bone development. Endocrinology 137:4250-4259, 1996.
243. Sakai R, Fujita S, Horie T, Ohyama T, Miwa K, Maki T, Okimoto N, Nakamura T, Eto Y. Activin increases bone mass and mechanical strength of lumbar vertebrae in aged ovariectomized rats. Bone 27:91-96, 2000.
244. Sakai R, Miwa K, Eto Y. Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 25:191-196, 1999.
245. Shuto T, Sarkar G, Bronk JT, Matsui N, Bolander ME. Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation. J Bone Miner Res 12:403-411, 1997.
246. Gaddy Kurten D, Coker JK, Abe E, Jilka RL, Manolaogas SC. Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures. Endocrinology 143:74-83, 2002.
247. Abe M, Shintani Y, Eto Y, Harada K, Fujinaka Y, Kosaka M, Matsumoto T. Interleukin-1 beta enhances and interferon-gamma suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts. Clin Exp Immunol 126:64-68, 2001.
248. Phillips DJ. Regulation of activin's access to the cell: Why is mother nature such a control freak? Bioessays 22:689-696, 2000.
249. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS. Measurement of dimeric inhibin-B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401-1405, 1996.
250. Woodruff TK, Krummen L, Chen SA, Lyon R, Hansen SE, DeGuzman G, Covello R, Mather J, Cossum P. Pharmacokinetic profile of recombinant human (rh) inhibin A and activin A in the immature rat. II. Tissue distribution of [125I]rh-inhibin A and [125I]rh-activin A in immature female and male rats. Endocrinology 132:725-734, 1993.
251. Draper LB, Matzuk MM, Roberts VJ, Cox E, Weiss J, Mather JP, Woodruff TK. Identification of an inhibin receptor in gonadal tumors from inhibin alpha-subunit knockout mice. J Biol Chem 273:398-403, 1998.
252. Chong H, Pangas SA, Bernard DJ, Wang E, Gitch J, Chen W, Draper LB, Cox ET, Woodruff TK. Structure and expression of a membrane component of the inhibin receptor system. Endocrinology 141:2600-2607, 2000.
253. Chapman SC, Woodruff TK. Modulation of activin signal transduction by inhibin-B and inhibin-binding protein (InhBP). Mol Endocrinol 15:668-679, 2001.
254. Esparza-Lopez J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, Lopez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factorbeta superfamily: Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 276:14588-14596, 2001.
255. Harrison CA, Farnworth PG, Chan KL, Stanton PG, Ooi GT, Findlay JK, Robertson DM. Identification of specific inhibin A-binding proteins on mouse Leydig (TM3) and sertoli (TM4) cell lines. Endocrinology 142:1393-1402, 2001.
256. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev 14:627-644, 2000.
257. Bernard DJ, Chapman SC, Woodruff TK. Mechanisms of inhibin signal transduction. Recent Prog Horm Res 56:417-450, 2001.
258. Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N, Guillemin R. Primary structure of the human follistatin precursor and its genomic organization. Proc Nat Acad Sci USA 85:4218-4222, 1988.
259. de Winter J, Ten Dijke P, de Vries CJM, van Achterberg TAE, Sugino H, De Waele P, Huylebroeck D, Verschueren K, Eijnden-van Raaij AJM. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Mol Cell Endo 116:105-114, 1996.
260. Shimonaka M, Inouye S, Shimasaki S, Ling N. Follistatin binds to both activin and inhibin through the common beta-subunit. Endocrinology 128:3313-3315, 1991.
261. Inouye S, Guo Y, Depaolo L, Shimonaka M, Ling N, Shimasaki S. Recombinant expression of human follistatin with 315 and 288 amino acids: Chemical and biological comparison with native porcine follistatin. Endocrinology 129:815-822, 1991.
262. Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, Ling N, Titani K, Sugino H. Molecular heterogeneity of follistatin, an activinbinding protein. J Biol Chem 68:15579-15587, 1993.
263. Hashimoto O, Kawasaki N, Tsuchida K, Shimasaki S, Hayakawa T, Sugino H. Difference between follistatin isoforms in the inhibition of activin signalling: Activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin. Cell Signal 12:565-571, 2000.
264. Inouye S, Ling N, Shimasaki S. Localization of the heparin binding site of follistatin. Mol Cell Endocrinol 90:1-6, 1992.
265. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino S. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. J Biol Chem 272:13835-13842, 1997.
266. Schneyer AL, Wang QF, Weiss J, Boepple P, Hall J, Khoury R, Taylor A, Pralong F, Sluss P, Crowley WF. Follistatin physiology and potential mechanisms of action in the human. In: Aono T, Sugino H. Vale WW, Eds. Inhibin, Activin and Follistatin: Regulatory Functions in System and Cell Biology, chap 3. New York: pp 28-38, 1997.
267. Sumitomo S, Inouye S, Liu X-J, Ling N, Shimasaki S. The heparin binding site of follistatin is involved in its interaction with activin. Biochem Biophys Res Commun 208:1-9, 1995.
268. Peng C, Mukai ST. Activins and their receptors in female reproduction. Biochem Cell Biol 78:261-279, 2000.
269. Hashimoto M, Shoda A, Inoue S, Yamada R, Kondo T, Sakurai T, Ueno N, Muramatsu M. Functional regulation of osteoblastic cells by the interaction of activin-A with follistatin. J Biol Chem 267:4999-5004, 1992.
270. Michel U, Farnsworth P, Findlay JK. Follistatins: More than folliclestimulating hormone suppressing proteins. Mol Cell Endocrinol 91:1-11, 1993.
271. Hemmati-Brivanlou A, Kelly OG, Melton DA. Follistatin, an antagonist of activin, is expressed in the Spemann Organizer and displays direct neuralizing activity. Cell 77:283-295, 1994.
272. Hemmati-Brivanlou A, Melton DA. Inhibition of activin receptor signaling promotes neuralization in Xenopus. Cell 77:273-281, 1994.
273. Graff JM. Embryonic patterning: to BMP or not to BMP, that is the question. Cell 89:171-174, 1997.
274. Patthy L, Nikolics K. Functions of agrin and agrin-related proteins. Trends Neurosci 16:76-81, 1993.
275. Hayette S, Gadoux M, Martel S, Bertrand S, Tigaud I, Magaud JP, Rimokh R. FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders. Oncogene 16:2949-2954, 1998.
276. Schneyer A, Tortoriello D, Sidis Y, Keutmann H, Matsuzaki T, Holmes W. Follistatin-related protein (FSRP): A new member of the follistatin gene family. Mol Cell Endocrinol 180:33-38, 2001.
277. Hohenester E, Maurer P, Timpl R. Crystal structure of a pair of follistatin-like and EF-hand calcium-binding dimains in BM-40. EMBO J 16:3778-3786, 1997.
278. Alliel PM, Perin JP, Jolles P, Bonnet FJ, Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur J Biochem 214:347-350, 1993.
279. Tsen G, Halfter W, Kroger S, Cole GJ. Agrin is a heparan sulfate proteoglycan. J Biol Chem 270:3392-3399, 1995.
280. Burgess RW, Skames WC, Sanes JR. Agrin isoforms with distinct amino termini: Differential expression, localization, and function. J Cell Biol 151:41-52, 2000.
281. Eib DW, Martens GJ. A novel transmembrane protein with epidermal growth factor and follistatin domains expressed in the hypothalamo-hypophysial axis of Xenopus laevis. J Neurochem 67:1047-1055, 1996.
282. Brekken RA, Sage EH. SPARC, a matricellular protein: At the crossroads of cell-matrix communication. Matrix Biol 19:816-827, 2001.
283. ++-binding sites modulate cell shape. J Cell Biol 111:3065-3076, 1998.
284. Sidis Y, Schneyer AL, Sluss PM, Johnson LN, Keutmann HT. Follistatin: Essential role for the N-terminal domain in activin binding and neutralization. J Biol Chem 276:17718-17726, 2001.
285. Wang Q, Keutmann HT, Schneyer AL, Sluss PM. Analysis of human follistatin structure: Identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins. Endocrinology 141:3183-3193, 2000.
286. Greenwald J, Fischer WH, Vale WW, Choe S. Three-finger toxin fold for the extracellular ligand-binding domain of the type II activin receptor serine kinase. Nat Struct Biol 6:18-22, 1999.
287. Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, Choe S, Vale W. Identification of a binding site on the type II activin receptor for activin and inhibin. J Biol Chem 275:3206-3212, 2000.
288. Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H. Identification and characterization of a novel follistatinlike protein as a binding protein for the TGF-beta family. J Biol Chem 275:40788-40796, 2000.
289. Tortoriello DV, Sidis Y, Holtzman DA, Holmes WE, Schneyer AL. Human follistatin-related protein: A structural homologue of follistatin with nuclear localization. Endocrinology 142:3426-3434, 2001.
290. Yamashita H, Ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH, Miyazono K. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 130:217-226, 1995.
291. Garner LW, Wolfman NM, Celeste AJ, Hattersley G, Hewick R, Rosen V. A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev Biol 208:222-232, 1999.
292. Fainsod A, Deissler K, Yelin R, Marom K, Epstein M, Pillemer G, Steinbeisser H, Blum M. The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mech Dev 63:39-50, 1997.
293. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A 95:9337-9342, 1998.
294. Wozney JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. (review) Clin Orthop 346:26-37, 1998.
295. Iemura I, Yamaoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci USA 95:9337-9342, 1998.
296. Federman S, Chen M, Garner M, Wolfman N, Celeste A. Binding of GDF-8 to the activin type IIB receptor is blocked by the GDF-8 propeptide and enhanced by the activin-binding protein follistatin. Proceedings of the 22nd Ann Mtg American Bone and Mineral Research, Toronto, 2000.
297. Massague J. TGF-beta signal transduction. Annu Rev Biochem 67:753-791, 1998.
298. Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1:169-178, 2000.
299. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13:2105-2124, 1999.
300. Pangas SA, Woodruff TK. Activin signal transduction pathways. Trends Endocrinol Metab 11:309-314, 2000.
301. Mathews LS. Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15:310-325, 1994.
302. Tsuchida K, Vaughan JM, Wiater E, Gaddy-kurten D, Vale WW. Inactivation of activin-dependent transcription by kinase-deficient activin receptors. Endocrinology 136:5493-5503, 1995.
303. Heldin CH, Miyazono K, Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997.
304. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MHI domain bound to DNA: Insights on DNA binding in TGF-beta signaling. Cell 94:585-594, 1998.
305. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP. A structural basis for mutational inactivation of the turnout suppressor Smad4. Nature 388:87-93, 1997.
306. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383:832-836, 1996.
307. Howell M, Itoh F, Pierreux CE, Valgeirsdottir S, Itoh S, Ten Dijke P, Hill CS. Xenopus Smad4beta is the co-Smad component of developmentally regulated transcription factor complexes responsible for induction of early mesodermal genes. Dev Biol 214:354-369, 1999.
308. Masuyama N, Hanafusa H, Kusakabe M, Shibuya H, Nishida E. Identification of two Smad4 proteins in Xenopus: Their common and distinct properties. J Biol Chem 274:12163-12170, 1999.
309. Liu F, Pouponnot C, Massague J. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev 11:3157-3167, 1997.
310. Kusanagi K, Kawabata M, Mishima HK, Miyazono K. Alpha-helix 2 in the amino-terminal mad homology 1 domain is responsible for specific DNA binding of Smad3. J Biol Chem 276:28155-28163, 2001.
311. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1:611-617, 1998.
312. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745-1754, 2000.
313. Labbe E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 2:109-120, 1998.
314. Kim J, Johnson K, Chen HJ, Carroll S, Laughon A. Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 388:304-308, 1997.
315. Kusanagi K, Inoue H, Ishidou Y, Mishima HK, Kawabata M, Miyazono K. Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol Biol Cell 11:555-565, 2000.
316. Yeo CY, Chen X, Whitman M. The role of FAST-1 and Smads in transcriptional regulation by activin during early Xenopus embryogenesis. J Biol Chem 274:26584-26590, 1999.
317. Attisano L, Silvestri C, Izzi L, Labbe E. The transcriptional role of Smads and FAST (FoxH1) in TGFbeta and activin signalling. Mol Cell Endocrinol 180:3-11, 2001.
318. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389:85-89, 1997.
319. Yeo CY, Chen X, Whitman M. The role of FAST-1 and Smads in transcriptional regulation by activin during early Xenopus embryogenesis. J Biol Chem 274:26584-26590, 1999.
320. Shimizu A, Kato M, Nakao A, Imamura T, Ten Dijke P, Heldin CH, Kawabata M, Shimada S, Miyazono K. Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Genes Cells 3:125-134, 1998.
321. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP, Roberts AB. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 276:19945-19953, 2001.
322. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 12:235-243, 2000.
323. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev 12:2153-2163, 1998.
324. Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev 12:2114-2119, 1998.
325. Pouponnot C, Jayaraman L, Massague J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem 273:22865-22868, 1998.
326. Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol Biol Cell 9:3309-3319, 1998.
327. Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K, Kawabata M. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads, J Biol Chem 274:35269-35277, 1999.
328. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFbeta signaling. Genes Dev 13:2196-2206, 1999.
329. Wotton D, Lo RS, Swaby LA, Massague J. Multiple modes of repression by the Smad transcriptional corepressor TGIF. J Biol Chem 274:37105-37110, 1999.
330. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274:584-594, 1999.
331. Letamendia A, Lastres P, Botella LM, Raab U, Langa C, Velasco B, Attisano L, Bemabeu C. Role of endoglin in cellular responses to transforming growth factor-beta: A comparative study with betaglycan. J Biol Chem 273:33011-33019, 1998.
332. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bemabeu C. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133:1109-1121, 1996.
333. Guerrero-Esteo M, Lastres P, Letamendia A, Perez-Alvarez MJ, Langa C, Lopez LA, Fabra A, Garcia-Pardo A, Vera S, Letarte M, Bernabeu C. Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 78:614-623, 1999.
334. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14:55-64, 2000.
335. Bourdeau A, Faughnan ME, Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 10:279-285, 2000.
336. Roelen BA, van Rooijen MA, Mummery CL. Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn 209:418-430, 1997.
337. Cheifetz S, Bellon T, Cales C, Vera S, Bemabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267:19027-19030, 1992.
338. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75:671-680, 1993.
339. Shen MM, Schier AF. The EGF-CFC gene family in vertebrate development. Trends Genet 16:303-309, 2000.
340. Yeo C, Whitman M. Nodal signals to Smads through Criptodependent and Cripto-independent mechanisms. Mol Cell 7:949-957, 2001.
341. Schier AF, Shen MM. Nodal signalling in vertebrate development. Nature 403:385-389, 2000.
342. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J, Niehrs C. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401:480-485, 1999.
343. Degen WG, Weterman MA, van Groningen JJ, Cornelissen IM, Lemmers JP, Agterbos MA, Geurts vK, Swart GW, Bloemers HP. Expression of nma, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts. Int J Cancer 65:460-465, 1996.
344. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95:779-791, 1998.
345. Goto D, Nakajima H, Mori Y, Kurasawa K, Kitamura N, Iwamoto I. Interaction between Smad anchor for receptor activation and Smad3 is not essential for TGF-beta/Smad3-mediated signaling. Biochem Biophys Res Commun 281:1100-1105, 2001.
346. Wurmser AE, Gary JD, Emr SD. Phosphoinositide 3-kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. J Biol Chem 274:9129-9132, 1999.
347. Miura S, Takeshita T, Asao H, Kimura Y, Murata K, Sasaki Y, Hanai JI, Beppu H, Tsukazaki T, Wrana JL, Miyazono K, Sugamura K. Hgs (Hrs). a FYVE domain protein, is involved in Smad signaling through cooperation with SARA. Mol Cell Biol 20:9346-9355, 2000.
348. Dong C, Li Z, Alvarez R Jr, Feng XH, Goldschmidt-Clermont PJ. Microtubule binding to Smads may regulate TGF beta activity. Mol Cell 5:27-34, 2000.
349. Lo RS, Massague J. Ubiquitin-dependent degradation of TGF-betaactivated smad2. Nat Cell Biol 1:472-478, 1999.
350. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400:687-693, 1999.
351. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12:186-197, 1998.
352. Bai S, Cao X. A nuclear antagonistic mechanism of I-Smads in TGF-β signaling. J Biol Chem 277:4176-4182, 2002.
353. Bai S, Shi X, Yang X, Cao X. Smad6 as a transcriptional corepressor. J Biol Chem 275:8267-8270, 2000.
354. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH. Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6:1365-1375, 2000.
355. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276:12477-12480, 2001.
356. Zhu HJ, Iaria J, Sizeland AM. Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem 274:32258-32264, 1999.
357. Kitamura K, Aota S, Sakamoto R, Yoshikawa SI, Okazaki K. Smad7 selectively interferes with different pathways of activin signaling and inhibits erythroid leukemia cell differentiation. Blood 95:3371-3379, 2000.
358. Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 9:274-279, 1999.
359. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397:710-713, 1999.
360. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP. A mechanism of suppression of TGF-3beta/SMAD signaling by NF-kappa B/Re1A. Genes Dev 14:187-197, 2000.
361. Kanamaru C, Yasuda H, Takeda M, Ueda N, Suzuki J, Tsuchida T, Mashima H. Ohnishi H, Fujita T. Smad7 is induced by norepinephrine and protects rat hepatocytes from activin A-induced growth inhibition. J Biol Chem 276:45636-45641, 2001.
362. Kretzschmar M, Liu F, Hata A, Doody J, Massague J. The TGF-beta family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. Genes Dev 11:984-995, 1997.
363. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 13:804-816, 1999.
364. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S. Regulation of Smad signaling by protein kinase C. FASEB J 15:553-555, 2001.
365. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 12:1587-1592, 1998.
366. Brown JD, DiChiara MR, Anderson KR, Gimbrone MA Jr, Topper JN. MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J Biol Chem 274:8797-8805, 1999.
367. Zimmerman CM, Kariapper MS, Mathews LS. Smad proteins physically interact with calmodulin. J Biol Chem 273:677-680, 1998.
368. Scherer A, Graff JM. Calmodulin differentially modulates Smad1 and Smad2 signaling. J Biol Chem 275:41430-41438, 2000.
369. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F. Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 276:42908-42914, 2001.
370. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature 371:297-300, 1994.
371. Heldin C, Miyazono K, Ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997.
372. Chen RH, Miettinen PJ, Maruoka EM, Choy L, Derynck R. A WD-domain protein that is associated with and phosphorylated by the type II TGF-beta receptor. Nature 377:548-552, 1995.
373. Choy L, Derynck R. The type II transforming growth factor (TGF)-beta receptor-interacting protein TRIP-1 acts as a modulator of the TGF-beta response. J Biol Chem 273:31455-31462, 1998.
374. Datta PK, Moses HL. STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol 20:3157-3167, 2000.
375. Griswold-Prenner I, Kamibayashi C, Maruoka EM, Mumby MC, Derynck R. Physical and functional interactions between type I transforming growth factor beta receptors and Balpha, a WD-40 repeat subunit of phosphatase 2A. Mol Cell Biol 18:6595-6604, 1998.
376. Ponting CP, Phillips C, Davies KE, Blake DJ. PDZ domains: Targeting signalling molecules to sub-membranous sites. Bioessays 19:469-479, 1997.
377. Garner CC, Nash J, Huganir RL. PDZ domains in synapse assembly and signalling. Trends Cell Biol 10:274-280, 2000.
378. Shoji H, Tsuchida K, Kishi H, Yamakawa N, Matsuzaki T, Liu Z, Nakamura T, Sugino H. Identification and characterization of a PDZ protein that interacts with activin type II receptors. J Biol Chem 275:5485-5492, 2000.
379. Blobe GC, Liu X, Fang SJ, How T, Lodish HF. A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling: Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein. GIPC. J Biol Chem 276:39608-39617, 2001.
380. Charng MJ, Zhang D, Kinnunen P, Schneider MD. A novel protein distinguishes between quiescent and activated forms of the type I transforming growth factor beta receptor. J Biol Chem 273:9365-9368, 1998.
381. Wurthner JU, Frank DB, Felici A, Green HM, Cao Z, Schneider MD, McNally JG, Lechleider RJ, Roberts AB. Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. J Biol Chem 276:19495-19502, 2001.
382. Mulder KM. Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth Factor Rev 11:23-35, 2000.
383. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, Ueno N, Nishida E, Shibuya H, Matsumoto K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAKI in the BMP signaling pathway. EMBO J 18:179-187, 1999.
384. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270:2008-2011, 1995.
385. Shibuya H, Yamaguchi K, Shirakabe K, Tonegawa A, Gotoh Y, Ueno N, Irie K, Nishida E, Matsumoto K. TAB1: An activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272:1179-1182, 1996.
386. Shibuya H, Iwata H, Masuyama N, Gotoh Y, Yamaguchi K, Irie K, Matsumoto K, Nishida E, Ueno N. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J 17:1019-1028, 1998.
387. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29:117-129, 2001.
388. Sano Y, Harada J, Tashiro S, Gotoh-Mandeville R, Maekawa T, Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 274:8949-8957, 1999.
389. Cocolakis E, Lemay S, Ali S, Lebrun JJ. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem 276:18430-18436, 2001.